In this article, we will be taking a look at the 12 Healthcare Stocks with Insider Buying in 2025.

In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, with divergent trends in technology adoption, investment, and fundraising. About $3 billion was raised in the first half of this year by U.S. healthcare venture capital (VC), which is a significant drop and might be the poorest year for healthcare fundraising in more than ten years. This slowdown is a result of macroeconomic factors that affect funding and operations, including rising interest rates, inflation worries, geopolitical tensions, and policy uncertainties. With significant activity in biopharma mergers, acquisitions, and strategic licensing agreements, the private healthcare markets continue to be robust in spite of these challenges.

One promising development in the industry is artificial intelligence (AI). Since 2022, the volume of healthtech AI deals has almost doubled, making it a major source of capital for innovation. Due to investor interest in AI solutions that enhance clinical decision support, imaging, and operational efficiency, digital health startups raised $6.4 billion in venture capital funding in the first half of 2025, up from $6 billion in the same period in 2024. Furthermore, China now plays a far bigger role in biopharma licensing—it spent $3 billion on transactions in H1 2025 alone, more than it did in 2024—but U.S. biopharma investment is still strong.

But there is a lot of pressure on the larger healthcare industry. On CNBC’s “The Exchange,” Mizuho healthcare strategist Jared Holz emphasized that the industry is experiencing unprecedented strain, with managed care and large-cap pharmaceuticals taking the brunt of the burden. He said that, aside from market downturns, healthcare has not outperformed the market in the last ten years, and that the current state of affairs is the worst the industry has seen in decades.

Strategic acquisitions, early-stage investments, and a possible resurgence in initial public offerings (IPOs) indicate that the industry is still ready for innovation in spite of these obstacles. Despite financial challenges, healthcare is poised for growth and revolution as AI-driven solutions increasingly address long-standing inefficiencies. The industry is at a critical juncture where it must balance technological advancements with economic challenges that could influence its course in the future.

With these trends in mind, we will now take a look at the healthcare stocks with Insider Buying in 2025.

Our Methodology

For our methodology, we began by screening stocks using the Stock Analysis screener, applying filters for a market capitalization above $2 billion and insider ownership greater than 20%. From the filtered results, we identified the companies with the highest insider ownership and ranked them in ascending order.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 12 healthcare stocks with Insider Buying in 2025.

12. Mesoblast Limited (NASDAQ:MESO)

Insider Shares: 33.76%

Mesoblast Limited (NASDAQ:MESO) is a global leader in developing allogeneic, off-the-shelf cellular medicines for inflammatory diseases. Using its proprietary mesenchymal lineage cell platform, the company targets severe and life-threatening conditions by modulating immune responses and promoting tissue repair. Its lead product, Ryoncil® (remestemcel-L), recently became the first FDA-approved allogeneic mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD). MESO is among the stocks with insider buying.

In late September 2025, Mesoblast Limited (NASDAQ:MESO) reaffirmed that all its cell therapy products, including Ryoncil®, are manufactured from U.S. donors in the United States and officially designated as U.S.-origin products. This designation exempts them from pharmaceutical import tariffs, giving the firm a significant commercial edge while underscoring its commitment to U.S.-based manufacturing and regulatory compliance.

Looking ahead, MESO is advancing the commercial launch of Ryoncil® while also progressing regulatory pathways for other therapies. Its Biologic License Application for Revascor®, aimed at treating ischemic heart failure, is under FDA review. At the same time, the business is expanding the development of rexlemestrocel-L for chronic conditions such as heart failure and low back pain.

11. ImmunityBio, Inc. (NASDAQ:IBRX)

Insider Shares: 43.07%

ImmunityBio, Inc. (NASDAQ:IBRX) is advancing its position as a leader in immunotherapy, focusing on cancer and immune disorders through its flagship therapy ANKTIVA®, which combines IL-15 superagonist N-803 with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG. The company is also expanding ANKTIVA’s use across new indications while progressing trials in lung cancer and lymphopenia.

In 2025, IBRX reported strong commercial momentum. Second-quarter revenue reached $26.4 million, up 60% from Q1, bringing year-to-date sales to $43 million. Since J-code approval streamlined reimbursement, unit sales have surged 246%. A lot of urology practices have joined the company’s Expanded Access Program for recombinant BCG, a move aimed at alleviating supply shortages and improving patient access. Internationally, the UK’s regulatory agency approved ANKTIVA plus BCG for BCG-unresponsive NMIBC carcinoma in situ, further broadening its market reach.

On the regulatory front, ImmunityBio, Inc. (NASDAQ:IBRX) is working closely with the FDA after receiving a Refuse-to-File letter for its supplemental biologics license application (sBLA) seeking expansion to papillary-only NMIBC. Meanwhile, the corporation is pushing for guideline updates through the National Comprehensive Cancer Network (NCCN), which could strengthen ANKTIVA’s adoption in U.S. clinical practice.

IBRX is also making progress in oncology trials. It launched the ResQ201A randomized trial evaluating N-803 with tislelizumab in second-line non-small cell lung cancer patients and is preparing international submissions for broader trial participation. Additionally, the FDA has shown support for the firm’s lymphopenia program, with expanded access now available for patients with solid tumors who failed first-line therapies.

To support these initiatives, ImmunityBio, Inc. (NASDAQ:IBRX) recently raised $80 million in equity financing, ensuring resources for ongoing regulatory discussions, clinical trials, and commercial expansion.

10. OPKO Health, Inc. (NASDAQ:OPK)

Insider Shares: 44.01%

OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations spanning diagnostics, pharmaceuticals, and innovative therapies. Its business is anchored by BioReference Laboratories and a growing pipeline focused on immuno-oncology, immune rejuvenation, and metabolic disorders such as obesity.

In 2025, the company drew attention with notable insider buying. CEO Phillip Frost, OPKO’s largest shareholder with roughly 31% ownership, joined other key investors in boosting stakes, bringing the top five holders’ combined ownership to 51%. Recent share purchases around $1.32 suggest strong insider confidence in the company’s long-term outlook.

On the clinical front, OPK advanced a Phase 1 Epstein-Barr virus (EBV) vaccine in partnership with Merck, testing safety in up to 200 healthy adults. Results could lead to Phase 2 trials as early as next year. Its ModeX division continues to drive innovation in immuno-oncology, with four candidates in the pipeline, including MDX2001, a tetraspecific antibody for solid tumors now in Phase 1 trials. Other programs target lymphoma, leukemia, and immune dysfunction. OPK is also among stocks with insider buying, reflecting confidence from key shareholders in its pipeline and strategic direction.

Beyond oncology, OPKO Health, Inc. (NASDAQ:OPK) is addressing metabolic disorders through a collaboration with Entera Bio on OPK-88006, an oral dual GLP-1/glucagon agonist for obesity. Data presented at ENDO 2025 showed encouraging pharmacologic and pharmacokinetic results, with both oral and injectable formulations in development to meet the growing demand for obesity treatments.

Financially, OPK reported Q2 2025 revenue of $156.8 million, reflecting a decline from the prior year. However, the business recently sold select oncology testing assets from BioReference to Labcorp, a move designed to streamline operations and improve liquidity. With projected 2025 revenues of $640–$660 million, OPK is leaning on its pipeline, cost savings, and strategic divestitures to strengthen margins and move toward profitability.